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Abstract
Background: We recently demonstrated that increased expression of the RNA-binding protein RBM3 is associated
with a favourable prognosis in breast cancer. The aim of this study was to examine the prognostic value of RBM3
mRNA and protein expression in epithelial ovarian cancer (EOC) and the cisplatin response upon RBM3 depletion
in a cisplatin-sensitive ovarian cancer cell line.
Methods: RBM3 mRNA expression was analysed in tumors from a cohort of 267 EOC cases (Cohort I) and RBM3
protein expression was analysed using immunohistochemistry (IHC) in an independent cohort of 154 prospectively
collected EOC cases (Cohort II). Kaplan Meier analysis and Cox proportional hazards modelling were applied to
assess the relationship between RBM3 and recurrence free survival (RFS) and overall survival (OS). Immunoblotting
and IHC were used to examine the expression of RBM3 in a cisplatin-resistant ovarian cancer cell line A2780-Cp70
and its cisplatin-responsive parental cell line A2780. The impact of RBM3 on cisplatin response in EOC was assessed
using siRNA-mediated silencing of RBM3 in A2780 cells followed by cell viability assay and cell cycle analysis.
Results: Increased RBM3 mRNA expression was associated with a prolonged RFS (HR = 0.64, 95% CI = 0.47-0.86,
p = 0.003) and OS (HR = 0.64, 95% CI = 0.44-0.95, p = 0.024) in Cohort I. Multivariate analysis confirmed that RBM3
mRNA expression was an independent predictor of a prolonged RFS, (HR = 0.61, 95% CI = 0.44-0.84, p = 0.003) and
OS (HR = 0.62, 95% CI = 0.41-0.95; p = 0.028) in Cohort I. In Cohort II, RBM3 protein expression was associated with
a prolonged OS (HR = 0.53, 95% CI = 0.35-0.79, p = 0.002) confirmed by multivariate analysis (HR = 0.61, 95% CI =
0.40-0.92, p = 0.017). RBM3 mRNA and protein expression levels were significantly higher in the cisplatin sensitive
A2780 cell line compared to the cisplatin resistant A2780-Cp70 derivative. siRNA-mediated silencing of RBM3
expression in the A2780 cells resulted in a decreased sensitivity to cisplatin as demonstrated by increased cell
viability and reduced proportion of cells arrested in the G2/M-phase.
Conclusions: These data demonstrate that RBM3 expression is associated with cisplatin sensitivity in vitro and with
a good prognosis in EOC. Taken together these findings suggest that RBM3 may be a useful prognostic and
treatment predictive marker in EOC.
Background
Epithelial ovarian cancer (EOC) is the leading cause of
death from gynaecological malignancy and the fifth
most common cause of cancer-related death in women.
The poor ratio of survival to incidence in EOC is related
to the high percentage of cases diagnosed at an
advanced stage and the lack of effective therapies for
advanced refractory disease. Despite improvements in
surgical techniques and the advent of more targeted
therapeutic agents, five year survival rates for EOC are
only 45% [1]. Such poor statistics indicate an urgent
requirement to improve on current understanding of
the molecular mechanisms underlying EOC, so as to
develop better early diagnostic and prognostic
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are required to guide current treatment protocols, as
well as to guide the development and application of new
targeted therapies.
Since its inception over 40 years ago, the platinum-
based agent cisplatin has had a major impact on cancer
therapy, particularly in the treatment of testicular and
ovarian cancer [2]. Standard treatment for advanced
EOC involves surgical debulking followed by adjuvant
chemotherapy with a combination of a platinum com-
pound (cisplatin or carboplatin) and taxane [3]. Despite
an initial response to cisplatin treatment, many patients
with EOC develop resistance to the drug and relapse
within a few years [4]. Cisplatin acts by forming covalent
bonds with purine DNA bases which causes cross-link-
ing of DNA and results in activation of several signal
transduction pathways involved in DNA-damage repair,
cell cycle arrest and apoptosis [2,5,6]. Several mechan-
isms have been implicated in cisplatin resistance, i.e.
decreased drug uptake, insufficient DNA-binding of the
drug, increased DNA-repair of cisplatin adducts and fail-
ure of induction of apoptosis, reviewed in [2,5,7].
The RNA binding motif protein 3, RBM3, is a glycine
rich protein containing a RNA-recognition motif (RRM)
through which it binds to both to DNA and RNA [8].
Proteins containing specific RRMs play an important
role in the stabilization of mRNA by reversibly binding
to conserved sequence elements, most often AU-rich
elements (AREs), in the untranslated regions (UTRs) of
the mRNA resulting in either stabilization or destabiliza-
tion of the mRNA [9]. The RBM proteins, 10 of which
have been described, contain between one and four
copies of the RRM consensus sequence [10]. The RRM
domain is evolutionary conserved across species and
found in virtually every cellular organelle in which RNA
is present suggesting an important but as yet not fully
understood functionality [10]. RBM3, initially identified
in a fetal brain cDNA library [11] is one of three X-
chromosome related RBM-genes (RBMX, RBM3,
RBM10) mapped to Xp11.23 [12] and is expressed in
various human fetal tissues as well as being one of the
earliest proteins induced by hypothermia [13]. Following
an antibody-based proteomics biomarker discovery strat-
egy using the Human Protein Atlas (HPA) (http://www.
proteinatlas.org) [14,15] we recently demonstrated an
association between nuclear RBM3 expression in breast
cancer and a significantly improved survival, particularly
in estrogen receptor (ER) positive tumors [16].
I nt h ep r e s e n ts t u d y ,t h ep r o g n o s t i cv a l u eo fR B M 3
was examined in two independent EOC cohorts, both at
the mRNA levels (Cohort I) and protein levels (Cohort
II), whereby RBM3 was found to be associated with a
good prognosis in both cohorts. RBM3 expression was
also examined in vitro using the cisplatin sensitive
ovarian cancer cell line A2780 and its cisplatin resistant
derivative A2780-Cp70. The relationship between RBM3
expression and cisplatin response in vitro was examined
using small interfering RNA (siRNA) mediated RBM3
knockdown in the A2780 cells which resulted in a
decreased sensitivity to cisplatin as demonstrated by an
increased cell viability and reduced proportion of cells
G2/M-phase arrest following cisplatin treatment.
Methods
Patients
Cohort I
Cohort I comprised of 285 cases of serous and endome-
troid carcinoma of the ovary, fallopian tube and perito-
neum. The cohort has been described previously [17].
The majority of patients underwent laparotomy for sta-
ging and debulking and subsequently received first-line
platinum/taxane based chemotherapy. In most cases,
tumor tissue was excised at the time of primary surgery,
prior to the administration of chemotherapy. Eighteen
patients who had received neoadjuvant platinum based
chemotherapy were also included in the cohort but
excluded from this study hence the total number or
patients examined was 267. Optimal debulking was
defined as less than 1 cm (diameter) residual disease,
and sub-optimal debulking was more than 1 cm (dia-
meter) residual disease. Recurrence-free survival (RFS)
was defined as the time interval between the date of
diagnosis and the first confirmed sign of disease recur-
rence based on GCIG definitions. Overall survival (OS)
was defined as the time interval between the date of his-
tological diagnosis and the date of death from any cause.
Median follow up was 29 months (range 0-214 months).
RNA was extracted from tumors and hybridized to
Affymetrix U133 Plus 2 arrays as previously described
[ 1 7 ] .C o m p l e t ee x p r e s s i o nd a t aw e r ed o w n l o a d e df r o m
GEO (http://www.ncbi.nlm.nih.gov/geo) (accession
GSE9899). R package ‘’Affy’’ (http://www.bioconductor.
org) was used to normalize the CEL files using the
RMA method [18]. For RBM3 analysis normalized gene
expression values were extracted from the dataset and
used without modification. Tumor samples were classi-
fied using a previously published method [19].
Cohort II
This cohort is a merge of all incident cases of epithe-
lial ovarian cancers in the large, population-based pro-
spective cohort studies Malmö Diet and Cancer Study
[20] (n = 101) and Malmö Preventive Medicine Study
[21] (n = 108) until Dec 31
st 2008. Thirty-five patients
participated in both studies, and archival tumor tissue
could be retrieved from 154 of the total number of
174 cases. After a median follow-up of 2.65 years
(range 0-21), 105 patients (68.2%) were dead and 49
(31.8%) alive.
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subtype and histological grade. Information regarding
clinical stage was obtained from the medical charts, fol-
lowing the standardized FIGO classification of tumor
staging. Information on residual tumor after surgery was
not available. Standard adjuvant therapy was platinum-
based chemotherapy, from the 1990s given in combina-
tion with paclitaxel.
Tissue microarray construction
Prior to TMA-construction, all cases were histopatholo-
gically re-evaluated on haematoxylin and eosin stained
slides. Areas representative of cancer were then marked
and TMAs constructed as previously described [22]. In
brief, 2-4 1.0 mm cores were taken from each tumor
and mounted in a new recipient block using a semi-
automated arraying device (TMArrayer; Pathology
Devices, Inc, Westminster, MD, USA).
RBM3 antibody generation and immunohistochemistry
PrEST [23,24] antigen was injected subcutaneously into
BALB/c mice (4-6 weeks old, female) at three weeks
intervals. The antigen was mixed with complete
Freund’s adjuvant for the first injection and incomplete
Freund’s adjuvant for the following injections. Three
days before infusion, the mouse was last challenged with
antigen intravenously. Hybridomas were generated by
fusion of mouse splenocytes with the Sp2/0 myeloma
cell line. Cell lines that showed positive results in
ELISA, Western blot (WB) and immunohistochemistry
(IHC) were selected for subcloning.
For immunohistochemical analysis of RBM3 in Cohort
II, 4 μm TMA-sections were automatically pretreated
using the PT-link system (DAKO, Copenhagen, Den-
mark) and then stained in a Techmate 500 (DAKO,
Copenhagen, Denmark) with the mouse monoclonal
anti-RBM3 antibody (AAb030038, Atlas Antibodies AB,
Stockholm, Sweden) diluted 1:5000. Estrogen receptor
(ER) and progesterone receptor (PR) expression were
assessed following, heat-mediated antigen retrieval
which was performed using microwave treatment for
2 × 5 min in a citrate buffer before being processed in
the Ventana Benchmark system (Ventana Medical
Systems Inc, AZ) using pre-diluted antibodies to ER
(Anti-ER, clone 6F11) and PR (Anti-PgR, clone 16).
Analysis of immunohistochemical staining
For assessment of nuclear RBM3 expression, both the
fraction of positive cells and staining intensity were
taken into account using a modification of the pre-
viously applied semiquantitative scoring system [16].
Nuclear fraction (NF) was categorized into four groups,
namely 0 (0-1%), 1 (2-25%), 2 (26-75) and 3 (> 75%)
and nuclear staining intensity (NI) denoted as 0-2,
whereby 0 = negative, 1 = intermediate and 2 = moder-
ate-strong intensity. A combined nuclear score (NS) of
NFxNI, which had a range of 0 to 6, was then con-
structed. Cytoplasmic staining intensity was denoted as
0 = negative, 1 = mild and 2 = moderate-strong, and
the fraction of positive cells not taken into account. ER
and PR negativity was defined as < 10% positively stain-
ing nuclei.
Cell lines and reagents
The human ovarian cancer cell line A2780 and the cis-
platin-resistant variant A2780-Cp70 (received as a gift
from Prof R Brown, Imperial College, London) were
maintained in RPMI-1640 supplemented with glutamine,
10% fetal bovine serum and 1% pencillin/streptomycin
in a humidified incubator of 5% CO2 at 37°C. Cisplatin
(Sigma-Aldrich, St. Louis, MO, USA) was dissolved in
0.9% NaCl to a stock solution of 1 mg/ml and added to
cells to the final concentration (1-100 μM).
Real-time quantitative PCR and Western Blotting
Total RNA isolation (RNeasy, QIAgen, Hilden, Ger-
many), cDNA synthesis (Reverse Transcriptase kit,
Applied Biosystems, Warrington, UK) and quantitative
real-time PCR (qRT-PCR) analysis with SYBR Green
PCR master mix (Applied Biosystems) were performed
as described [25,26]. Quantification of expression levels
were calculated by using the comparative Ct method,
normalization according to house keeping genes; HMBS
(forward primer: 5′- G G CA A TG C GG C TG C AA - 3 ′,
reverse primer: 5′-GGG TAC CCA CGC GAA TCA C-
3′), SDHA (forward primer: 5′-TGG GAA CAA GAG
GGC ATC TG-3′, reverse primer 5′-CCA CCA CTG
CAT CAA ATT CAT G-3′)a n dU B C( f o r w a r dp r i m e r :
5′-ATT TGG GTC GCG GTT CTT G-3′, reverse pri-
mer: 5′-TGC CTT GAC ATT CTC GAT GGT-3′). For
RBM3 amplification, forward primer with sequence 5′-
CTT CAG CAG TTT CGG ACC TA-3′ and reverse pri-
mer with sequence 5′-ACC ATC CAG AGA CTC TCC
GT-3′ were used. All primers were designed using Pri-
mer Express (Applied Biosystems).
For immunoblotting, cells were lysed in ice-cold lysis
buffer (150 mM NaCl, 50 mM Tris-HCL pH 7.5, 1%
Triton X-100, 50 mM NaF, 1 mM Na3VO4, 1 mM phe-
nylmethylsulfonyl fluoride (PMSF)) and supplemented
with protease inhibitor cocktail Complete Mini (Roche,
Basel, Switzerland). For Western blotting, 20-50 μgo f
protein were separated on 15% SDS-PAGE gels and
transferred onto nitrocellulose membranes (Hybond
ECL, Amersham Pharmacia Biotech, Buckinghamshire,
UK). The membranes were probed with primary antibo-
dies followed by horseradish peroxidase (HRP)-conju-
gated secondary antibodies (Amersham Life Science,
Alesbury, U.K.) and visualized using the Enhanced
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films (Amersham Pharmacia Biotech). RBM3 was
detected by the mouse monoclonal anti-RBM3 antibody
(AAb030038, Atlas Antibodies AB, Stockholm, Sweden)
diluted 1:500 in blocking solution (5% BSA, 1× PBS,
0.1% Tween20), Bax by a polyclonal antibody (BD Phar-
mingen, San Diego, CA, USA) diluted 1:1000 and Bcl-2
using a monoclonal antibody diluted 1:250 (Santa Cruz,
Biotechnology, Santa Cruz, CA, USA). Membranes were
stripped and re-probed with an anti-b-actin antibody
(Santa Cruz, Biotechnology, Santa Cruz, CA, USA) at a
dilution of 1:1000, to provide a loading control.
Cell pellet arrays
Cell lines were fixed in 4% formalin and processed in
gradient alcohols. Cell pellets were cleared in xylene and
washed multiple times in molten paraffin. Once pro-
cessed, cell lines were arrayed in duplicate 1.0 mm cores
using a manual tissue arrayer (Beecher Inc, WI) and
IHC was performed on 4 μm sections using the RBM3
1B5 antibody diluted 1:1000.
siRNA knockdown of RBM3 gene expression
Transfection with siRNA against RBM3 (Applied Biosys-
tems, Carlsbad, Ca) or control siRNA (Applied Biosys-
tems) was performed with Lipofectamine 2000
(Invitrogen, Carlsbad, CA) with a final concentration of
50 nM siRNA. All siRNA experiments were performed
using three independent RNA oligonucleotides (#58, #59
and #60) targeting RBM3.
WST-1 cell viability assay
The effect of cisplatin on cell viability was determined
by the WST-1 assay (Roche Applied Science, Man-
nheim, Germany) according to the manufacturer’s
recommendation. A2780 and A2780-Cp70 cells were
seeded in 96-well plates at the density of 2500 cells/well
in 100 μl appropriate medium a day before addition of
cisplatin. Cells were treated with cisplatin (0-100 μM)
for 1 h followed by 24, 48 or 72 hrs recovery in fresh
drug-free media. Samples were made in triplicate. Ten
microliters WST-1 solution was added per well and
incubated at 37°C for 4 hrs. The absorbance of each
well was measured using a scanning multiwell spectro-
photometer, ELISA reader, at the wavelength of 450 nm
and reference wavelength of 690 nm.
Flow cytometry
For cell cycle phase analysis, cells were fixed in 70%
ethanol for 30 minutes at -20°C followed with washing
with PBS and centrifugation. In order to label DNA, pel-
lets were resuspended in Vindelöv solution (3.5 μM
Tris-HCl pH 7.6, 10 mM NaCl, 10 μg/ml propidium
iodide, 20 ug/ml RNase and 0.1% v/v NP40) and
incubated in the dark for 20 minutes on ice. The cell
cycle analysis was performed by flow cytometry analysis
using FACS Calibur (BD Biosciencies, San José, CA),
counting in total 1 × 10
4 cells. Gating of G0/G1-, S-
and G2/M-populations was performed manually using
t h eF l o w J os o f t w a r e( v e r s i o n6 . 4 . 7 ,T r e eS t a r ,I n c .A s h -
land, OR).
The fraction of apoptotic and necrotic cells were ana-
lyzed by flow cytometry using AnnexinV-APC and
7AAD (BD Pharmingen, San Diego, CA) staining
according to manufacturer’s instructions. Briefly, cells
were harvested by trypsinization, washed twice in cold
PBS and resuspended in 1× Annexin V Binding buffer
(BD Pharmingen, San Diego, CA). Cells were stained
with AnnexinV-APC antibody and 7AAD and subjected
to flow cytometric analysis using a FACSCalibur flow
cytometry (BD Biosciencies, San José, CA) to determine
the percentage of AnnexinV and 7AAD positive cells.
The results are given as the mean of three independent
experiments, bars indicate standard error of mean.
Statistics
Spearman’s Rho, Chi-square and Kruskal-Wallis tests
were used for comparison of RBM3 expression and rele-
vant clinicopathological characteristics. Kaplan-Meier
analysis and log rank test were used to illustrate differ-
ences in recurrence free survival (RFS) and overall sur-
vival (OS) according to RBM3 expression. Cox
regression proportional hazards models were used to
estimate the impact of RBM3 expression on RFS and
OS in both uni- and multivariate analysis, adjusted for
stage and differentiation grade (both cohorts) and
volume of residual tumor (0 vs > 0) in Cohort I.
Patients who had received neoadjuvant chemotherapy in
Cohort I (n = 18) were excluded from the survival ana-
lyses. All calculations were performed using SPSS ver-
sion 15.0 (SPSS Inc, Chicago, IL). All statistical tests
were two-sided and a p value < 0.05 was considered sta-
tistically significant. The experimental data are
expressed as mean ± SEM of at least three independent
experiments. Statistical significance of differences
between means was determined by one-way ANOVA
followed by Duncan’s multiple range test or Student’s
t-test.
Results
Validation of the RBM3 antibody
The specificity of the RBM3 antibody was confirmed by
siRNA-mediated knockdown of RBM3 in A2780 cells.
IHC performed on formalin fixed, paraffin embedded
siRNA transfected A2780 cells revealed a marked
decrease in immunoreactivity in the RBM3 knockdown
cells compared to controls as visualized by IHC on cell
pellets (Fig. 1A) and Western blotting (Fig. 1B).
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characteristics in epithelial ovarian cancer
Having previously demonstrated that RBM3 was asso-
ciated with a less aggressive breast cancer phenotype
[16] we sought to examine the relationship between
RBM3 mRNA and protein expression and clinicopatho-
logical characteristics in two independent EOC cohorts.
In Cohort I, increased RBM3 mRNA levels were not
associated with any clinicopathological characteristics
(Table 1).
In Cohort II, following antibody optimisation and stain-
ing, it was possible to evaluate the expression of RBM3
protein in 151 cases (98%). Images representing different
patterns of expression are shown in Figure 1C. Using the
combined score, 57 (38%) tumors lacked RBM3 nuclear
RBM3 staining, and 94 (63%) tumors expressed RBM3 in
various intensities and fractions. For statistical purposes,
tumors were grouped into negative = 0 (combined NS
0-1), intermediate = 1 (combined NS 2-3) and strong = 2
(combined NS > 3). As visualized in Table 1, RBM3 NS
was not associated with histological subtype, disease stage
or differentiation grade. Cytoplasmic staining was only
present in 27 (18%) cases, and therefore not accounted
for in the statistics. There was no significant association
between RBM3 and ER or PR expression (data not
shown).
Increased RBM3 mRNA levels and protein expression are
associated with a prolonged survival in ovarian cancer
patients
We proceeded to investigate the relationship between
RBM3 expression and clinical outcome. In Cohort I,
Figure 1 Specificity of the RBM3 antibody tested in A2780 ovarian cancer cells and immunohistochemical RBM3 expression in primary
ovarian tumors. RBM3 protein expression was significantly decreased after transfection with siRNA against RBM3 in A2780 cells as shown by (A)
immunocytochemistry 48 hrs post-transfection and (B) Western blot 48 and 72 hrs post-transfection. (C) Staining of RBM3 was denoted as (i)
negative (nuclear score = 0), (ii) intermediate (nuclear score = 1-2) and (iii) strong (nuclear score > 2).
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RBM3 mRNA levels were associated with a significantly
prolonged RFS and OS (Fig. 2A and 2B). Cox univariate
analysis confirmed this association with an improved
RFS (HR = 0.64, 95% CI = 0.47-0.86, p = 0.003)a n dO S
(HR = 0.64, 95% CI = 0.44-0.95, p = 0.024)( T a b l e2 ) .
Multivariate analysis controlling for age, disease stage,
differentiation grade and residual tumor volume (Table
2) confirmed that RBM3 expression was an independent
predictor of RFS (HR = 0.61, 95% CI = 0.44-0.84, p=
0.003) and OS (HR = 0.62, 95% CI = 0.41-0.95; p=
0.028). The independent beneficial prognostic value of
RBM3 expression for both RFS and OS was retained
when subset analysis of tumours of pure ovarian origin
(n = 243) was performed (data not shown).
In Cohort II, Kaplan Meier analysis revealed a step-
wise association between RBM3 expression and OS
whereby RBM3 positive tumors had a significantly
improved OS compared to RBM3 negative tumors (Fig.
2C), justifying a dichotomisation into negative versus
any expression (Fig. 2D). Cox regression analysis showed
a significantly improved OS for RBM3 positive tumors
in both univariate (HR = 0.53, 95% CI = 0.35-0.79, p=
0.002), and multivariate analysis (HR = 0.61, 95% CI =
0.40-0.92, p = 0.017), adjusted for age, stage and differ-
entiation grade (Table 2).
RBM3 levels are higher in cisplatin-sensitive than
cisplatin-resistant ovarian cancer cells
RBM3 protein expression, assessed by both Western
blotting and IHC, was higher in the parental A2780
cells compared to their cisplatin-resistant derivative
A2780-Cp70 (Fig. 3A and 3B). Real-time quantitative
PCR (qRT-PCR) confirmed a similar difference whereby
there was a three fold higher level of RBM3 mRNA in
the A2780 compared to the A2780-Cp70 cell line (Fig.
3C). As RBM3 has been found to be associated with
proliferation [27,28], we compared the growth rate of
t h et w oc e l ll i n e s ,a n dw e r eu n a b l et od e m o n s t r a t ea n y
significant differences in proliferation (Fig. 3D).
Cell viability assay confirmed cisplatin resistance in
the A2780-Cp70 cells relative to the A2780 cells (p<
0.05; Fig. 3E). The proportion of cells arrested in G2/M
(Fig. 3F) and apoptotic/necrotic cells (Fig. 3G) following
cisplatin treatment was also significantly reduced in the
A2780-Cp70 cells. Notably, there was a significant dif-
ference in cell cycle phase distribution between
untreated A2780 and A2780-Cp70 cells (Fig. 3F) with a
Table 1 Correlations between clinicopathological characteristics and RBM3 mRNA (Cohort I) levels and protein
expression (Cohort II)
Cohort I Cohort II
RBM3 score low high 0 1 2
n (% for columns) 120 (45.6) 143 (54.4) p-value 74 (49.0) 50 (33.1) 27 (17.9) p-value
Histological subtype
mucinuos 0 (0.0) 0 (0.0) 0.887
† 4 (5.4) 4 (8.0) 3 (11.1) 0.395
†
serous 111 (92.5) 133 (93.0) 42 (56.8) 31 (62.0) 16 (59.3)
endometroid 9 (7.5) 9 (6.3) 17 (23.0) 12 (24.0) 5 (18.5)
clear cell 0 (0.0) 0 (0.0) 6 (8.1) 1 (2.0) 2 (7.4)
Brenner 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.7)
adenocarcinoma nos 0 (0.0) 1 (0.7) 5 (6.8) 2 (4.0) 0 (0.0)
Differentiation grade
high 3 (2.5) 14 (9.8) 0.079 2 (2.7) 2 (4.0) 3 (11.1) 0.084
intermediate 40 (33.3) 48 (33.6) 17 (23.0) 13 (26.0) 9 (33.3)
low 77 (64.2) 78 (54.5) 55 (74.3) 35 (70.0) 15 (55.6)
missing 0 (0.0) 3 (2.1) 0 (0.0) 0 (0.0) 0 (0.0)
Stage
I 9 (7.5) 15 (10.5) 0.070 14 (18.9) 7 (14.0) 5 (18.5) 0.760
II 3 (2.5) 15 (10.5) 5 (6.8) 9 (18.0) 3 (11.1)
III 101 (84.2) 104 (72.7) 40 (54.1) 26 (52.0) 8 (29.6)
IV 7 (5.8) 9 (6.3) 9 (12.2) 6 (12.0) 7 (25.9)
missing 0 (0.0) 0 (0.0) 6 (8.1) 2 (4.0) 4 (14.8)
Correlations were calculated using Spearman correlation test unless other specified.
†Kruskal-Wallis test (two-sided).
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cells, but no significant difference in apoptosis (Fig. 3G)
was observed. However, there was a trend towards a
higher fraction of apoptotic cells in untreated A2780-
Cp70 cells.
Downregulation of RBM3 significantly reduces cisplatin
sensitivity in ovarian cancer cells
The relationship between RBM3 and cisplatin response
was then examined using siRNA mediated gene silen-
cing, whereby the cisplatin-sensitive A2780 cells were
transfected with three different RBM3-specific siRNA:s
or scrambled control siRNA prior to cisplatin treatment.
Subsequent determination of cisplatin response as mea-
sured by cell cytotoxicity assay and cell cycle analysis
revealed that RBM3 knockdown in A2780 cells
significantly decreased their sensitivity to cisplatin (Fig.
4A). This effect was evident for three independent
RBM3-specific siRNAs. Furthermore, cisplatin induced
G2/M arrest was significantly less pronounced in
siRBM3 transfected A2780 cells compared to si-control
transfected cells (Fig. 4B). There was also a decreased,
however non-significant, percentage of apoptotic cells in
siRBM3 transfected cells compared to controls (Fig. 4C).
Given the previously demonstrated relationship
between RBM3 and apoptosis-regulating proteins [29],
we also compared the levels of Bcl-2 and Bax in siRBM3
transfected cells and controls. In line with previous find-
ings [30], Bcl-2 could barely be detected in the A2780
cells while elevated levels were observed in A2780-Cp70
cells. (Additional file 1A). In A2780-Cp70 cells, Bax
levels were lower than in A2780 cells, but Bax levels
Figure 2 Increased mRNA (Cohort I) and protein expression (Cohort II) of RBM3 are associated with a prolonged survival. Kaplan Meier
analysis of recurrence free survival (A) and overall survival (B) according to RBM3 mRNA levels in Cohort I. Kaplan Meier analysis of overall
survival according to immunohistochemical RBM3 staining in Cohort II in strata defined as (C) negative, intermediate and strong expression and
(D) negative versus positive expression.
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RBM3 (Additional file 1B-C).
Cisplatin treatment did not affect RBM3 protein
expression or the siRNA mediated down-regulation of
RBM3 (Additional file 2). The effects of RBM3 down-
regulation in A2780 cells in the absence of cisplatin
were also investigated and, in agreement with previous
studies [27], siRBM3 transfected A2780 cells showed a
significantly reduced cell viability, a slightly higher pro-
portion of cells in G2/M and no effect on apoptosis
(Additional file 3).
Discussion
This investigation of the prognostic value of RBM3 in
EOC reveals that RBM3 is an independent prognostic
marker at both mRNA and protein levels. Gene expres-
sion analysis in a cohort of 267 EOC cases showed that
high RBM3 mRNA expression was an independent pre-
dictor of a significantly improved RFS and OS. Immuno-
histochemical analysis in an independent cohort of 154
EOC cases demonstrated that RBM3 protein expression
was associated with a significantly improved OS in uni-
variate and multivariate analysis. This is in line with
previous findings from two independent breast cancer
cohorts where RBM3 was associated with more favour-
able clinicopathological parameters and a significantly
improved survival, irrespective of adjuvant treatment
[16]. However, since platinum-based chemotherapy is a
fundamental aspect of current EOC treatment regimens,
we hypothesized that RBM3 might enhance platinum-
sensitivity in vitro. We initially confirmed lower RBM3
protein levels in the cisplatin-resistant ovarian cancer
cell line A2780-Cp70 compared to their parental cispla-
tin-sensitive A2780 cells and using RNAi techniques, we
demonstrated that silencing of RBM3 led to a decreased
cisplatin response in ovarian cancer cells.
Taken together, these data demonstrate that RBM3 is
a marker of good prognosis in EOC and a predictor of
response to platinum-based chemotherapy, most likely a
combination of both, particularly in the light of the pre-
viously demonstrated good prognosis associated with
RBM3 expression in breast cancer patients, where the
vast majority of patients received no adjuvant systemic
chemotherapy [16]. While future in-depth studies are
warranted to further elucidate the functional mechan-
isms underlying RBM3’s role in cisplatin-mediated cell
death, the in vitro data presented here provide sufficient
evidence to support the hypothesis that, in addition to
being a beneficial prognostic biomarker, RBM3 might
also predict cisplatin response in EOC. Further studies
are required to evaluate the role of RBM3 in predicting
response to other platinum based agents, particularly in
the setting of a prospective randomised control trial
whereby stratification according to different treatment
regimens can be performed.
Some aspects on the results presented here merit
further attention. The reduced cytotoxic effect of cispla-
tin in siRBM3 transfected cells was to a large extent
reflected by cell cycle alterations, e.g. a lower percentage
of cells arrested in G2/M phase rather than by a
decreased percentage of apoptotic cells. Cisplatin treat-
ment is known to induce both cell cycle arrest and
Table 2 Cox uni- and multivariate analysis of recurrence free and overall survival according to RBM3 mRNA levels
(Cohort I) and protein expression (Cohort II)
Recurrence free survival Overall survival
HR (95% CI) p-value HR (95% CI) p-value
Cohort I
Univariate Univariate
low (n = 115, nevent = 85) 1.00 (n = 115, nevent = 54) 1.00
high (n = 142, nevent = 89) 0.64 (0.47-0.86) 0.003 (n = 139, nevent = 50) 0.64 (0.44-0.95) 0.024
Multivariate Multivariate
low (n = 103, nevent = 77) 1.00 (n = 103, nevent = 51) 1.00
high (n = 119, nevent = 71) 0.61 (0.44-0.84) 0.003 (n = 117, nevent = 50) 0.62 (0.41-0.95) 0.028
Cohort II
Univariate
negative x x x x (n = 74, nevent = 33) 1.00
positive x x x x (n = 77, nevent = 44) 0.53 (0.35-0.79) 0.002
Multivariate
negative x x x x (n = 68, nevent = 29) 1.00
positive x x x x (n = 71, nevent = 42) 0.61 (0.40-0.92) 0.017
Multivariate analysis included adjustment for age (continuous) stage (I-II vs III-IV), grade (I-II vs III) and residual disease (none vs any, only available for Cohort I).
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A2780 cells. However, while cisplatin treatment resulted
in a significantly decreased cell cycle arrest in siRBM3
transfected A2780 cells, the percentage of apoptotic
cells was not significantly reduced. Notably, despite
being one of the most cisplatin sensitive ovarian cancer
cell lines, A2780 cells have been shown to have a rela-
tively low percentage of apoptotic cells following cispla-
tin treatment [30]. As there was no evident difference in
cell cycle characteristics between siRBM3-transfected
and control-transfected A2780 cells without cisplatin
treatment, but yet a significantly reduced proportion of
siRBM3 treated cells in G2/M-phase arrest following
cisplatin treatment, the main effects of RBM3 on cispla-
tin sensitivity might be reflected in cell cycle distribution
rather than apoptosis. Although RBM3 mRNA expres-
sion has previously been associated with the pro-apopto-
tic Bax gene in breast cancer [29], we were unable to
demonstrate a down-regulation of Bax protein in
siRBM3 transfected A2780 cells, further supporting the
theory that RBM3 promotes cisplatin sensitivity through
cell-cycle regulation.
It is evident that RBM3 is up-regulated in response to
various conditions causing cellular stress, i.e. hypother-
mia [13,31,32] hypoxia [26], serum starvation [28] and
exposure to microgravity [33]. We did not see an
Figure 3 Expression of RBM3 in the cisplatin-sensitive A2780 ovarian cancer cell line compared to the cisplatin-resistant cell line
A2780-Cp70 and the effects of cisplatin treatment on viability, cell cycle phase distribution and apoptosis in A2780 and A2780-Cp70
cell lines. (A) Immunocytochemical staining and (B) immunoblotting of RBM3 showing substantially lower RBM3 protein expression in the
cisplatin-resistant A2780-Cp70 cell line compared to its parental cisplatin-sensitive A2780 cell line. (C) Relative mRNA expression was also reduced
in the A2780-Cp70 cells compared to A2780 cells as shown by qRT-PCR analysis. Data shown are mean ± SEM of a representative experiment of
two independent experiments performed in triplicate. (D) Cell growth illustrated as viability ratio 48:24 and 72:24 hrs measured by WST-1
demonstrating no difference between A2780 and A2780-Cp70 cells. Data shown are mean ± SEM of a representative experiment of three
independent experiments performed in triplicate (E) Cell viability was evaluated by WST-1 assay in A2780 and A2780-Cp70 cells treated with
cisplatin (1, 5, 10, 25, 50 and 100 μM) for 1 h followed by 48 hrs culture in fresh drug-free media. Data are presented as mean values from four
independent experiments performed in triplicates presented as percentage of viable cells as compared with untreated cells. Error bars represent
SEM. (F-G) A2780 and A2780-Cp70 cells were treated with 50 μM cisplatin for 1 h followed by 48 hrs culture in fresh drug-free media followed
by flow cytometric analysis of (F) cell cycle phase distribution and (G) fraction of apoptotic cells. Data are presented as mean value from three
independent experiments presented as fold change of cisplatin treatment. Error bars represent SEM.
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however, it would still be of interest to investigate the
potential role of RBM3 in DNA repair response given
the observed decrease of RBM3-silenced cells arrested
in G2/M upon cisplatin treatment.
Apart from our previous study in breast cancer [16],
there are to our knowledge no other published data on
the prognostic impact of tumor-specific RBM3 expres-
sion in human cancer. However, RBM3 has been iden-
tified as one of five down-regulated genes in an in
vitro model of melanoma progression [34], implying a
beneficial impact on prognosis also in this cancer
form. Contrasting in vitro data have also been pub-
lished, whereby RBM3 has been proposed to be a
proto-oncogene stabilizing COX-2 mRNA levels and
protecting against mitotic catastrophe in colorectal
cancer cell lines [27].
A common observation in human tissue is that RBM3
is up-regulated in cancer [27,28] and in proliferating
non-malignant cells [28], compared to normal cells.
Quite in line with these findings, we found that siRNA
mediated knockdown of RBM3 resulted in reduced pro-
liferation in A2780 cells, which might in part explain
the reduced cisplatin sensitivity and also the relatively
modest reduction in apoptosis upon treatment in
siRBM3 transfected A2780 cells. Yet, as a consequence
of the observation that RBM3 seems to be necessary for
the maintenance of cellular integrity during various
stress conditions, it has been hypothesized that targeting
RBM3 could prove to be an efficient novel therapeutic
strategy against cancer [27,35]. This viewpoint is chal-
lenged by the results presented here, but, evidently, drug
induced effects by RBM3 modulation seem to differ
between different cell line models, as down-regulation of
RBM3 has been associated with enhanced response to
adriamycin and cisplatin in androgen dependent but not
androgen-independent prostate cancer cells [35]. To
what extent this variation is true in human tumors
Figure 4 Down-regulation of RBM3 significantly reduces cisplatin sensitivity in ovarian cancer cells. siRBM3 transfected A2780 cells were,
24 hrs post-transfection, treated with various concentrations of cisplatin for 1 h followed by 48 hrs culture in fresh drug-free media. (A) Cell
viability was evaluated by WST-1 assay in siRBM3 transfected A2780 cells treated with cisplatin (1, 5, 10, 25, 50 and 100 μM). Data are presented
as mean values from six independent experiments performed in triplicates presented as percentage of viable cells as compared with untreated
cells. Error bars represent SEM. (B) Cell cycle phase distribution and (C) fraction of apoptotic cells were analysed by flow cytometry in siRBM3
transfected A2780 cells treated with 50 μM cisplatin. Data are presented as mean value from four independent experiments presented as fold
change of cisplatin treatment. Error bars represent SEM.
Ehlén et al. Journal of Translational Medicine 2010, 8:78
http://www.translational-medicine.com/content/8/1/78
Page 10 of 12remains to be elucidated but to our knowledge, in con-
trast to ovarian cancer, prostate cancer is not routinely
treated with platinum-based chemotherapeutic agents. It
should also be emphasized that, in a translational con-
text, the proposal that RBM3 is a proto-oncogene acti-
vated in response to adverse cellular conditions [27]
d o e sn o tc o n t r a d i c tt h ef i n d i n g st h a ti t sp r e s e n c ei na n
established tumor is associated with a favourable patient
outcome as such findings would not have taken patient
treatment into account.
The coincidence of a beneficial prognostic impact of
RBM3 expression in EOC both at the mRNA and pro-
tein level demonstrated here is particularly relevant
from a translational perspective as it would justify using
IHC, which is a simpler, faster and less costly method
than RT-PCR in the clinical setting. In our previous
study in breast cancer [16], the favourable prognostic
impact of RBM3 was assessed by IHC in two indepen-
dent patients cohorts using a polyclonal, monospecific
antibody, initially developed within the HPA programme
[23,36]. In the present study, the favourable prognostic
impact of RBM3 expression in EOC was demonstrated
at both the gene expression and protein levels in two
relatively large independent cohorts. RBM3 protein
expression was assessed using a monoclonal antibody
which displayed a single band of the expected size on
Western blot and further validation showed a decreased
RBM3 expression in siRNA transfected A2780 cells
compared to controls, both as assessed by IHC and
Western blotting. Notably, t h ep r e v i o u s l yu s e dp o l y c l o -
nal antibody has also been validated in the A2780 cells
with similar results to the monoclonal antibody; e.g. dif-
ferential expression in A2780 and A2780-Cp70 cells and
decreased expression in siRNA transfected cells (data
not shown). Furthermore, analysis of the tumor speci-
mens in Cohort II using the antibody that was used in
the breast cancer study [16] yielded concordant results
regarding the prognostic impact of tumor-specific
RBM3 expression (data not shown).
In breast cancer, nuclear RBM3 expression was asso-
ciated with favourable clinicopathological parameters,
including hormone receptor status [16]. In this study,
we found no association between RBM3 and ER or PR
expression in EOC as assessed by IHC. This observation
indicates that RBM3 might have different functions in
the context of estrogen-related signalling in breast can-
cer and ovarian cancer. The potential clinical relevance
of this is however less evident as the beneficial effect of
high RBM3 expression in breast cancer was independent
of tamoxifen treatment.
Conclusions
Here, we present data from two independent patient
cohorts demonstrating that expression of the RNA-
binding protein RBM3, both at the mRNA and protein
levels, is associated with a good prognosis in epithelial
ovarian cancer. Furthermore, we show that decreased
RBM3 expression confers reduced platinum sensitivity
in ovarian cancer cells. These findings indicate that
RBM3 may be a useful prognostic and treatment predic-
tive marker in epithelial ovarian cancer.
Additional material
Additional file 1: Expression of the apoptosis regulating proteins
Bcl-2 and Bax in A2780 and A2780-Cp70 cells and siRBM3
transfected A2780 cells compared to controls. Western blot analysis
of (A) Bcl2 expression in A2780, A2780-Cp70 and siRBM3 transfected
A2780 cells and Bax expression in (B) A2780 and A2780-Cp70 cells and
(C) siRBM3 transfected A2780 cells.
Additional file 2: Cisplatin treatment does not affect the protein
level of RBM3 or the siRNA-mediated down-regulation of RBM3. (A)
Protein expression of RBM3 was examined by immunoblotting in A2780
cells treated with various concentrations of cisplatin for 1 h followed by
48 hrs culture in fresh drug-free media. (B) siRBM3 transfected A2780
cells were, 24 hrs post-transfection, treated with 50 μM cisplatin for 1 h
followed by 48 hrs culture in fresh drug-free media whereby RBM3
remained down-regulated as shown by immunoblotting.
Additional file 3: The effects of RBM3 down-regulation on cell
viability, cell cycle characteristics and apoptosis in A2780 cells. (A)
Cell viability was evaluated by WST-1 assay in siRBM3 transfected A2780
cells. Data are presented as mean values from five independent
experiments performed in triplicates presented as percentage of viable
cells relative to si-control transfected cells. Error bars represent SEM. (B)
Cell cycle phase distribution and (C) fraction of apoptotic cells were
analysed by flow cytometry in siRBM3 transfected A2780 cells. Data are
presented as mean value from four independent experiments. Error bars
represent SEM.
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